T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.
T&R Biofab Co. Ltd (246710) - Total Assets
Latest total assets as of September 2025: ₩83.86 Billion KRW
Based on the latest financial reports, T&R Biofab Co. Ltd (246710) holds total assets worth ₩83.86 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
T&R Biofab Co. Ltd - Total Assets Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
T&R Biofab Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
T&R Biofab Co. Ltd's total assets of ₩83.86 Billion consist of 26.7% current assets and 73.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩16.67 Billion | 16.9% |
| Accounts Receivable | ₩2.20 Billion | 2.2% |
| Inventory | ₩4.72 Billion | 4.8% |
| Property, Plant & Equipment | ₩61.33 Billion | 62.3% |
| Intangible Assets | ₩1.33 Billion | 1.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how T&R Biofab Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: T&R Biofab Co. Ltd's current assets represent 26.7% of total assets in 2024, a decrease from 55.9% in 2015.
- Cash Position: Cash and equivalents constituted 16.9% of total assets in 2024, down from 53.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 62.3% of total assets.
T&R Biofab Co. Ltd Competitors by Total Assets
Key competitors of T&R Biofab Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
T&R Biofab Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - T&R Biofab Co. Ltd generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - T&R Biofab Co. Ltd is currently not profitable relative to its asset base.
T&R Biofab Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.42 | 0.85 | 35.42 |
| Quick Ratio | 0.32 | 0.76 | 32.46 |
| Cash Ratio | 0.00 | 0.39 | 0.00 |
| Working Capital | ₩-22.87 Billion | ₩ -6.02 Billion | ₩ 41.62 Billion |
T&R Biofab Co. Ltd - Advanced Valuation Insights
This section examines the relationship between T&R Biofab Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.91 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.4% |
| Total Assets | ₩98.45 Billion |
| Market Capitalization | $38.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values T&R Biofab Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: T&R Biofab Co. Ltd's assets decreased by 1.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for T&R Biofab Co. Ltd (2015–2024)
The table below shows the annual total assets of T&R Biofab Co. Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩98.45 Billion | -1.37% |
| 2023-12-31 | ₩99.82 Billion | +31.44% |
| 2022-12-31 | ₩75.94 Billion | -7.66% |
| 2021-12-31 | ₩82.23 Billion | +69.54% |
| 2020-12-31 | ₩48.51 Billion | +79.07% |
| 2019-12-31 | ₩27.09 Billion | -12.91% |
| 2018-12-31 | ₩31.10 Billion | +228.56% |
| 2017-12-31 | ₩9.47 Billion | -1.27% |
| 2016-12-31 | ₩9.59 Billion | +75.95% |
| 2015-12-31 | ₩5.45 Billion | -- |